The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.